Holen Sie sich die Stockscreener-App
37.74
0.34%
-0.13
Handel nachbörslich:
37.74
Schlusskurs vom Vortag:
$37.87
Offen:
$37.92
24-Stunden-Volumen:
194.46K
Relative Volume:
0.58
Marktkapitalisierung:
$2.08B
Einnahmen:
$651.97M
Nettoeinkommen (Verlust:
$59.71M
KGV:
35.28
EPS:
1.0696
Netto-Cashflow:
$172.03M
1W Leistung:
+0.67%
1M Leistung:
+4.20%
6M Leistung:
+30.36%
1J Leistung:
+35.22%
1-Tages-Spanne:
$37.27
$38.13
1-Wochen-Bereich:
$37.08
$38.68
52-Wochen-Spanne:
$25.53
$39.37
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Firmenname
Supernus Pharmaceuticals Inc
Sektor
Telefon
301-838-2500
Adresse
9715 KEY WEST AVENUE, ROCKVILLE, MD
Vergleichen Sie SUPN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
37.74 | 2.08B | 651.97M | 59.71M | 172.03M | 1.0696 |
|
ZTS
Zoetis Inc
|
165.89 | 74.84B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.24 | 41.78B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
12.92 | 40.96B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.92 | 24.83B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
143.26 | 14.50B | 2.24B | 385.90M | 440.10M | 3.73 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-09-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-01-03 | Fortgesetzt | Jefferies | Buy |
| 2021-12-01 | Fortgesetzt | Jefferies | Buy |
| 2021-04-13 | Hochstufung | Jefferies | Hold → Buy |
| 2020-06-16 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-06-15 | Fortgesetzt | Jefferies | Hold |
| 2019-11-08 | Herabstufung | Berenberg | Buy → Hold |
| 2019-11-07 | Herabstufung | Stifel | Buy → Hold |
| 2019-11-06 | Herabstufung | Jefferies | Buy → Hold |
| 2018-11-12 | Bestätigt | B. Riley FBR | Buy |
| 2018-01-18 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-12-28 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-12-04 | Hochstufung | Janney | Neutral → Buy |
| 2017-11-08 | Hochstufung | Stifel | Hold → Buy |
| 2017-10-19 | Eingeleitet | FBR & Co. | Buy |
| 2017-09-19 | Herabstufung | Stifel | Buy → Hold |
| 2017-07-17 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-07-14 | Eingeleitet | Janney | Neutral |
| 2017-06-01 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-07-18 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2016-07-18 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2016-02-08 | Hochstufung | Jefferies | Hold → Buy |
| 2015-11-05 | Bestätigt | Northland Capital | Outperform |
| 2015-10-28 | Eingeleitet | Northland Capital | Outperform |
Alle ansehen
Supernus Pharmaceuticals Inc Aktie (SUPN) Neueste Nachrichten
Supernus Pharmaceuticals, Inc. Enters into Lease Agreement for Approximately 136,016 Square Feet for its New Headquarters with Advent Key West, LLC - Marketscreener.com
Hennion & Walsh Asset Management Inc. Acquires 25,004 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Burney Co. Raises Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Bought by JPMorgan Chase & Co. - Defense World
Despite the downward trend in earnings at Supernus Pharmaceuticals (NASDAQ:SUPN) the stock advances 3.1%, bringing five-year gains to 56% - Simply Wall St
Multiple Sclerosis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Epidemiology, Therapies and Companies by DelveInsight - The Globe and Mail
SUPN (Supernus Pharmaceuticals) Intrinsic Value: DCF (FCF B - GuruFocus.com
(SUPN) Investment Report - Stock Traders Daily
Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 9.4% CAGR over the last five years - Yahoo Finance
Supernus Pharmaceuticals (NASDAQ:SUPN) Now Covered by Cantor Fitzgerald - Defense World
Supernus Pharmaceuticals (NASDAQ:SUPN) Now Covered by Analysts at Cantor Fitzgerald - MarketBeat
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Bought by Principal Financial Group Inc. - Defense World
Principal Financial Group Inc. Has $8.90 Million Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Franklin Resources Inc. Increases Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Where are the Opportunities in (SUPN) - Stock Traders Daily
Jane Street Group LLC Cuts Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Barclays PLC Grows Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Geode Capital Management LLC Has $46.22 Million Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stock Holdings Lifted by Barclays PLC - Defense World
Geode Capital Management LLC Grows Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
HighTower Advisors LLC Takes $264,000 Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Stifel Financial Corp Increases Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Wellington Management Group LLP - MarketBeat
Fmr LLC Buys 8,499 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
(SUPN) Trading Signals - Stock Traders Daily
Knight Therapeutics Announces Filing of New Drug Submission for Qelbree® (viloxazine) in Canada - GlobeNewswire
Thinking about buying stock in BigBear.ai, Supernus Pharmaceuticals, Collegium Pharmaceutical, Duolingo, or Cryptoblox Technologies? - Marketscreener.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $2.50 Million Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
SUPN (Supernus Pharmaceuticals) 3-Year EPS without NRI Grow - GuruFocus.com
Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Gap UpWhat's Next? - MarketBeat
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ? - Simply Wall St
Ashford Capital Management Inc. Trims Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Quantbot Technologies LP Sells 21,601 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
28,185 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Bought by Systematic Financial Management LP - MarketBeat
How To Trade (SUPN) - Stock Traders Daily
Charles Schwab Investment Management Inc. Purchases 91,354 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Charles Schwab Investment Management Inc. Acquires 91,354 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Supernus Pharmaceuticals executive sells shares worth $788,436 By Investing.com - Investing.com Canada
Supernus Pharmaceuticals executive sells shares worth $788,436 - Investing.com
Supernus Pharmaceuticals, Inc. Announces FDA Acceptance for Review of New Drug Application for SPN-812 for the Treatment of ADHD - Marketscreener.com
Intech Investment Management LLC Purchases 1,838 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
PDT Partners LLC Buys Shares of 37,110 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference - The Manila Times
C21 Investments Inc (CXXI-CN) QuotePress Release - The Globe and Mail
Big Rock Brewery Inc (BR-T) QuotePress Release - The Globe and Mail
Supernus Pharmaceuticals CEO to Present at Piper Sandler Healthcare Conference | SUPN Stock News - StockTitan
Loomis Sayles & Co. L P Has $47.27 Million Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Evertz Technologies Ltd (ET-T) QuotePress Release - The Globe and Mail
Apple Inc (AAPL-Q) QuotePress Release - The Globe and Mail
Segall Bryant & Hamill LLC Acquires New Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
SUPN (Supernus Pharmaceuticals) Operating Margin % : 22.67% (As of Sep. 2024) - GuruFocus.com
Finanzdaten der Supernus Pharmaceuticals Inc-Aktie (SUPN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.94%
0.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):